ScholarLens Back to search
2023•Value in HealthOpen access

EE430 Cost-Effectiveness of Tremelimumab or Tremelimumab in Combination with Durvalumab Vs Durvalumab As Treatment of Advanced Hepatocellular Carcinoma

Tian Tang, Lizheng Shi

Open full text 1 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Tremelimumab, Durvalumab, Hepatocellular carcinoma, Medicine, Sorafenib, Oncology, Internal medicine, Immunotherapy

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
EE430 Cost-Effectiveness of Tremelimumab or Tremelimumab in Combination with Durvalumab Vs Durvalumab As Treatment of Advanced Hepatocellular Carcinoma — Research Paper | ScholarLens